Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia.
Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia.
Indian Heart J. 2023 Jul-Aug;75(4):229-235. doi: 10.1016/j.ihj.2023.05.006. Epub 2023 May 18.
Microalbuminuria has been elevated as an outcome predictor in cardiovascular medicine. However, due to the small number of studies investigating the association of microalbuminuria and mortality in the coronary heart disease (CHD) population, the prognosis value of microalbuminuria in CHD remains under debate. The objective of this meta-analysis was to investigate the relationship between microalbuminuria and mortality in individuals with CHD.
A comprehensive literature search was performed using Pubmed, EuroPMC, Science Direct, and Google Scholar from 2000 to September 2022. Only prospective studies investigating microalbuminuria and mortality in CHD patients were selected. The pooled effect estimate was reported as risk ratio (RR).
5176 patients from eight prospective observational studies were included in this meta-analysis. Individuals with CHD have a greater overall risk of all-cause mortality (ACM) [rR = 2.07 (95% CI = 1.70-2.44); p = 0.0003; I = 0.0%] as well as cardiovascular mortality (CVM) [rR = 3.23 (95% CI = 2.06-4.39), p < 0.0001; I = 0.0%]. Subgroup analysis based on follow-up duration and a subset of CHD patients were similarly associated with an increased risk of ACM.
This meta-analysis indicates that microalbuminuria is associated with a higher risk of mortality in individuals with CHD. Microalbuminuria can serve as a predictor of poor outcomes in CHD patients.
微量白蛋白尿已被提升为心血管医学的预后指标。然而,由于研究微量白蛋白尿与冠心病(CHD)人群死亡率之间关系的研究数量较少,微量白蛋白尿在 CHD 中的预后价值仍存在争议。本荟萃分析的目的是探讨微量白蛋白尿与 CHD 患者死亡率之间的关系。
从 2000 年至 2022 年 9 月,使用 Pubmed、EuroPMC、Science Direct 和 Google Scholar 进行了全面的文献检索。仅选择了前瞻性研究微量白蛋白尿与 CHD 患者死亡率之间关系的研究。汇总效应估计值以风险比(RR)报告。
本荟萃分析纳入了 8 项前瞻性观察性研究的 5176 名患者。CHD 患者的全因死亡率(ACM)[RR=2.07(95%CI=1.70-2.44);p=0.0003;I=0.0%]和心血管死亡率(CVM)[RR=3.23(95%CI=2.06-4.39),p<0.0001;I=0.0%]总体风险更高。基于随访时间和 CHD 患者亚组的亚组分析同样与 ACM 风险增加相关。
本荟萃分析表明,微量白蛋白尿与 CHD 患者的死亡率升高相关。微量白蛋白尿可作为 CHD 患者不良预后的预测指标。